Date	Name	Title	Type	Shares Traded	Price Range
Jun 5, 2007	bloch stephen m	Director	Acquisition (Non Open Market)	2,050,790	n/a
Jun 5, 2007	canaan equity partners iii llc	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	2,050,790	n/a
Jun 5, 2007	barkas alexander e	Director	Acquisition (Non Open Market)	2,232,060	n/a
Jun 5, 2007	prospect venture partners ii lp	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	2,232,060	n/a
Jun 5, 2007	fhm iv lp	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	2,600,014	n/a
Jun 5, 2007	topper james n	Director	Acquisition (Non Open Market)	2,600,014	n/a
Jul 17, 2012	glaxosmithkline plc	Beneficial Owner (10% or more)	Buy	2,949,581	6.30
Jun 5, 2007	new enterprise associates 11 lp	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	3,650,488	n/a
Jun 5, 2007	barris peter j	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	4,472,224	n/a
Jun 5, 2007	kramlich c richard	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	4,472,224	n/a
Jun 5, 2007	newhall charles w iii	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	4,472,224	n/a
Jun 5, 2007	perry mark w	Beneficial Owner (10% or more)	Acquisition (Non Open Market)	4,472,224	n/a
Showing 381-392 of 392 transactions Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  See Previous 20

Stock transaction information provided by EDGAR Online. Amicus Therapeutics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.